BALA CYNWYD, Pa., April 10, 2013 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Life Technologies Corp. ("Life" or the "Company") (Nasdaq: LIFE) relating to the reported buyout.
Life said in January that it was working with Deutsche Bank AG, as well as Moelis & Co., on a strategic review. It has been reported that bids may have been received by Life from two bidders at $66.00 and $69.00 for each share of Life. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Life for not acting in the Company's shareholders' best interests in connection with the sale process. The market for gene tests, like the one sold by Life, may grow to $25 billion within a decade as more doctors use a patient's genetic makeup to tailor treatments. In addition, an analyst has set a price target for Life stock at $75.00 per share.
If you own shares of Life stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org visiting http://brodsky-smith.com/564-life-life-technologies-corp.html, by calling toll free 877-LEGAL-90.
Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE Brodsky & Smith, LLC